Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
about
Arsenic Disruption of DNA Damage Responses-Potential Role in Carcinogenesis and ChemotherapyExit from arsenite-induced mitotic arrest is p53 dependentBIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and -resistant ovarian cancer cellsArsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activationSodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)Arsenic trioxide, a therapeutic agent for APL.From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.Application status of tamoxifen in endocrine therapy for early breast cancer.Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responsesArsenic trioxide: an anti cancer missile with multiple warheads.Prevention of breast cancer: current state of the science and future opportunities.Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?Protective effects of oxymatrine against arsenic trioxide-induced liver injury.Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres.Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors.Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers.Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway.Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines.Arsenic trioxide-induced neuroblastoma cell death is accompanied by proteolytic activation of nuclear Bax.Indomethacin-enhanced anticancer effect of arsenic trioxide in A549 cell line: involvement of apoptosis and phospho-ERK and p38 MAPK pathwaysCamalexin induces apoptosis in T-leukemia Jurkat cells by increased concentration of reactive oxygen species and activation of caspase-8 and caspase-9.Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein.Attenuation of arsenic trioxide induced cardiotoxicity through flaxseed oil in experimental rats.Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2.Synergistic Effects of Arsenic Trioxide and Radiation: Triggering the Intrinsic Pathway of Apoptosis.
P2860
Q26781256-C98E0C80-4707-48CF-B7CF-7F53CFB41754Q28391168-13DF3910-5A92-46EA-9727-7AFE6DE7CBBAQ28478390-B95A5194-A00F-41F5-81F7-CD6D9D2E842AQ28539034-4B48B31D-F17E-403C-848B-1F8F123BC453Q33940195-6E038218-12F4-4E10-9EA3-B5B1A202C925Q34435492-47708183-2769-4270-9FD3-6DF31C43B9C1Q35117568-2881D9B2-DEAB-487D-BD8B-480D0BB08ACFQ35758139-74881444-60FA-488F-90A3-7FFEC2AD1E9CQ35800229-D457B713-0226-419E-BB68-82DD9A2D3801Q35892810-FC8E9DD4-1EBC-41FB-A6BE-8611AF5AB269Q36194579-40872BAA-D3B1-428A-B90D-AB4D92BB536BQ36654338-82EF115C-76FC-4277-AD88-822007C24E6BQ36824250-0B6295D3-D845-4085-9159-E2728250D8FEQ37029829-2EF9983C-5138-4192-AACD-F1620BFCC568Q37085878-C048633C-7B5F-4655-99E8-BDB66B605DF1Q37512764-94BEBF66-78D3-4CB9-AEC6-768DF0BC99E6Q37706494-B0E4B3B4-335E-4438-8BF8-8506B6FA2D30Q38636360-88F919D3-D18B-47CB-985A-F18E646A5FDCQ38945222-46E6C6C7-C75E-4E22-8C3F-920823F4F38BQ39155982-4AFDBEBB-FE41-4CFC-8F23-A066CA887B87Q39634173-99EF4445-560E-4160-9A84-4799E48EABCDQ40135330-3D6DA9D5-7668-4388-8E34-E9580A55104DQ40150435-15E84176-9426-483B-A2FD-A9D8A3101E5BQ42095313-2DD2BFAB-E293-4428-B00A-682F6747A819Q44407199-26B57D2E-08ED-4EED-BE54-11A4CAD50BCFQ47842837-1F32B69C-C9D6-48AA-A83F-5BD36DF1EF22Q48226667-A5DB7E31-7C9C-430B-A53A-37052954F321Q52584360-D6412BFB-3FC2-4FA2-9C44-9D3CE6540996Q54987791-B35E68F0-976C-419E-990A-DDF19ED6FCEA
P2860
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@ast
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@en
type
label
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@ast
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@en
prefLabel
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@ast
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@en
P2093
P1433
P1476
Drug approval summaries: arsen ...... azole, paclitaxel, bexarotene.
@en
P2093
Flamm Honig S
Hirschfeld S
Johnson JR
O'Leary JJ
Williams GA
P356
10.1634/THEONCOLOGIST.6-1-4
P577
2001-01-01T00:00:00Z